These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30458751)

  • 1. Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.
    Jiang Y; Zhang J; Huang J; Xu B; Li N; Cao L; Zhao M
    BMC Pulm Med; 2018 Nov; 18(1):171. PubMed ID: 30458751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
    Markóczy Z; Sárosi V; Kudaba I; Gálffy G; Turay ÜY; Demirkazik A; Purkalne G; Somfay A; Pápai-Székely Z; Rásó E; Ostoros G
    BMC Cancer; 2018 May; 18(1):598. PubMed ID: 29801465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
    Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
    Katakami N; Yokoyama T; Morita S; Okamoto T; Urata Y; Hattori Y; Iwamoto Y; Sato Y; Ikeda N; Takahashi T; Daga H; Oguri T; Fujisaka Y; Nishino K; Sugawara S; Kozuki T; Oki M; Yamamoto N; Nakagawa K
    Int J Clin Oncol; 2023 Jan; 28(1):79-88. PubMed ID: 36414827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
    Lu RL; Hu CP; Yang HP; Li YY; Gu QH; Wu L
    Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N; Hanafi A; Jayusman M
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
    Yang H; He D; Wang F; Deng Q; Xie Z
    Clin Exp Metastasis; 2020 Jun; 37(3):391-399. PubMed ID: 32356218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
    Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
    J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
    Iuchi T; Shingyoji M; Sakaida T; Hatano K; Nagano O; Itakura M; Kageyama H; Yokoi S; Hasegawa Y; Kawasaki K; Iizasa T
    Lung Cancer; 2013 Nov; 82(2):282-7. PubMed ID: 24021541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
    Ruiz-Patiño A; Castro CD; Ricaurte LM; Cardona AF; Rojas L; Zatarain-Barrón ZL; Wills B; Reguart N; Carranza H; Vargas C; Otero J; Corrales L; Martín C; Archila P; Rodriguez J; Avila J; Bravo M; Pino LE; Rosell R; Arrieta O;
    Target Oncol; 2018 Oct; 13(5):621-629. PubMed ID: 30284706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
    Gerber NK; Yamada Y; Rimner A; Shi W; Riely GJ; Beal K; Yu HA; Chan TA; Zhang Z; Wu AJ
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):322-9. PubMed ID: 24679729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.